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ABSTRACT
Introduction: Opioid-induced constipation
(OIC) is a common and costly side effect of
opioid treatment affecting patients’ quality of
life (QoL). The combination
oxycodone/naloxone reduces OIC while
providing effective analgesia in patients with
moderate to severe pain. The objective of this
observational study was to compare
health-related quality of life (HRQoL),
healthcare resource use, and costs in patients
with severe pain who were initially treated with
oxycodone and laxatives and then subsequently
switched to treatment with
oxycodone/naloxone.
Methods: Data were collected by means of
questionnaires completed by patients with
OIC before and after the initiation of
oxycodone/naloxone treatment at different
clinical centers in Sweden. The questionnaires
included questions on healthcare resource use
and absence from work and also consisted of the
Patient Assessment of Constipation-QoL
(PAC-QoL) instrument, the EuroQol five
dimensions questionnaire (EQ-5D), the Patient
Assessment of Constipation Symptoms
(PAC-SYM) instrument, and the Bowel
Function Index (BFI).
Results: The analysis included 37 patients.
Resource utilization was lower after treatment
with oxycodone/naloxone, in terms of both the
number of healthcare contacts and the
purchases of medicine for the treatment of
constipation. According to the BFI score,
patients had fewer problems with OIC after
the initiation of oxycodone/naloxone. The
PAC-QoL score showed a positive change for
patients in both the 96-point dissatisfaction
index and the 16-point satisfaction index.
PAC-SYM scores was lower after the initiation
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of oxycodone/naloxone treatment, indicating
fewer constipation-related problems.
Conclusion: Treatment with
oxycodone/naloxone had an overall positive
effect on patients, consisting mainly of
decreasing the severity of the constipation
problems, increasing HRQoL, and decreasing
the use of healthcare resources.
Funding: Mundipharma AB, Gothenburg,
Sweden.
Keywords: Costs; Laxatives; Naloxone;
Opioid-induced constipation; Oxycodone;
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INTRODUCTION
Opioids are used for moderate to severe pain
caused by cancer [1], trauma, and operations.
Opioid therapy may be considered in
combination with non-pharmacological and
non-opioid therapies for selected patients
suffering from severe nonmalignant persistent
pain [2]. However, treatment with potent
opioids is connected with frequent and
problematic side effects [3]. One of the most
common side effects is opioid-induced
constipation (OIC). In a publication based on
patient data from a Swedish noninterventional
study, the conclusion was that OIC is a costly
complication that also affects the quality of life
(QoL) of patients. The complication may also
limit effective pain therapy [4].
Oxycodone/naloxone is an opioid analgesic
combined with an opioid antagonist in a fixed
prolonged-release combination which has been
shown to significantly reduce opioid-induced
constipation while providing effective analgesia
in patients with moderate to severe
non-malignant pain [5]. Oxycodone/naloxone
has also been confirmed to be well tolerated and
efficacious in patients suffering from moderate
to severe cancer pain [6].
The objective of the observational study was
to compare health-related QoL (HRQoL),
healthcare resource use, and costs in patients
with severe pain, treated with oxycodone and
laxatives, who were subsequently switched to
treatment with oxycodone/naloxone.
METHODS
The study (OXN9513 GAIN) was an observational
study of patients with severe pain treated with
opioids in Sweden. Patients treated with
oxycodone in a stable, adequate dose and time
period with symptoms of OIC despite laxatives
were enrolled in the study. The participating
patients served as their own controls, and data
for comparison were therefore collected
retrospectively before the initiation of
oxycodone/naloxone treatment and after
initiation of treatment with
oxycodone/naloxone. The prescription of
oxycodone/naloxone was clearly separated from
the decision to include the patient in the study.
The observational study consisted of two
visits, i.e., before (visit 1) and after (visit 2) the
initiation of oxycodone/naloxone treatment,
covering a total period of 8 weeks, as
illustrated in Fig. 1. The results from visit 1 are
thus related to the situation when patients were
treated with oxycodone and laxatives, while the
results from visit 2 correspond to the situation
when patients had switched to treatment with
oxycodone/naloxone. In both cases the survey
answers deal with the last 4 weeks before the
visit, i.e., all collected data were retrospective.
The primary data sources were patient
questionnaires, which were filled out by
patients with OIC before and after the
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initiation of oxycodone/naloxone treatment,
and a case report form (CRF) filled out by the
clinical investigator. The CRF contained
questions about patient characteristics, cause
of pain, drug treatment, adverse events, and
classification of pain. The physician also
completed the clinician-administered,
patient-reported Bowel Function Index (BFI)
before and after the initiation of
oxycodone/naloxone treatment. The answers
to the BFI correspond to the patients’
experience of bowel function during the
previous 7 days.
Before and after the initiation of
oxycodone/naloxone, the patient completed
questionnaires with two self-administered
disease-specific instruments, namely, the
Patient Assessment of Constipation-QoL
(PAC-QoL) and the Patient Assessment of
Constipation Symptoms (PAC-SYM)
instruments. PAC-QoL assesses the degree to
which constipation has reduced the patient’s
QoL during the previous 2 weeks, and the
associated PAC-SYM measures the
constipation-related symptoms during the
same 2 weeks. Patients were also asked to
complete the generic quality-of-life instrument
EuroQol five dimensions (EQ-5D) together with
the EuroQoL visual analog scale (EQ-VAS).
Patients also completed a separate survey at
visit 1 and visit 2 that included questions on
their resource utilization in the 4 weeks before
and after initiation of oxycodone/naloxone
treatment, respectively. These questions were
aimed at obtaining patient-specific information
on constipation and/or pain-related additional
visits or telephone contacts with physicians and
other caregivers, inpatient care, and purchases
of laxatives. The patient survey also included
questions on employment, absence from work
and ability to work.
The general structure of the reported values
from the different instruments and forms
consisted of the values before and after the
initiation of oxycodone/naloxone and the
difference between them. The calculation of
the change in HRQoL was performed by
subtracting the reported value before the
initiation of oxycodone/naloxone from the
reported value after the initiation of
oxycodone/naloxone. The HRQoL estimate
based on the EQ-5D questionnaire was
calculated using the weights from Dolan [7].
The indices for patient assessment of PAC-QoL
and PAC-SYM scores were calculated according
to Sharma and Agarwal [8].
The daily dose of oxycodone/naloxone was
calculated as the average daily dose during the
4-week period if a patient had been prescribed
varying doses. Costs for laxatives were
calculated based on 28 days for those patients
who reported the use of sodium picosulphate,
polyethylene glycol or both [9]. Other
pharmaceutical costs were calculated
Fig. 1 Observation period
Pain Ther (2016) 5:227–236 229
according to AUP prices (retail/pharmacy-level
prices) from FASS (Pharmaceutical Specialties in
Sweden) [10]. The unit costs for other direct
costs, such as healthcare visits, telephone
consultations, and inpatient days, were based
on the price list for the Southern Health Care
Region in 2015, which is one of the most
detailed sources of information on the costs of
health care resources in Sweden [11] (Table 1).
All costs were calculated in Swedish krona (SEK),
2015 prices, and are presented in euros (EUR).
The average exchange rates in 2015 were 1
USD = SEK8.435 and 1 EUR = SEK9.356 [12].
Descriptive statistical analyses were
performed to describe the patient population,
including sex, age, and background pain and
constipation characteristics. Descriptive
analyses of variables of pharmacotherapy and
resource use for the period before and after the
initiation of oxycodone/naloxone were also
performed. Continuous variables were
described by the mean and standard deviation
(SD) and by the median with minimum and
maximum values, as appropriate. Categorical
variables were reported using numbers and
proportions. For the QoL variables the
difference between before and after the
initiation of oxycodone/naloxone was tested
using a paired t test. The statistical tests were
two-sided, and the significance level was set as
0.05. All analyses were performed using STATA
release 14 (StataCorp LP, College Station, TX).
Compliance with Ethics Guidelines
Ethical approval for the study was obtained by
the Regional Ethical Board in Lund in 2013 (Dnr
2013/25 and 2013/28), and all procedures
followed were in accordance with the Helsinki
Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients included in the study.
RESULTS
Patients were recruited from June 2013 to April
2015 from ten different clinical centers in
Sweden. The majority of the participating
centers were specialized pain clinics. In total,
37 patients treated with oxycodone and
laxatives were included in the study, and data
from both before and after the initiation of
oxycodone/naloxone were available for the
most central variables for 31 patients. The
number of patients who responded differs
between the different questionnaires. Patient
characteristics are presented in Table 2.
The total number of visits to caregivers and
telephone contacts was higher in the 4-week
period before the initiation of
oxycodone/naloxone treatment than in the






Telephone contact specialist physician 72.25
Telephone contact general practitioner 52.05
Telephone contact nurse 34.63




2 sachets per dayb
0.38
Laxative (sodium picosulphate) 10
drops per dayb
0.12
Laxative (enemas) package 4 9 5 ml 6.31
a Average of oncology, neurology, and orthopedic ward
b Assumptions
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4-week period immediately thereafter, although
the number of nurse visits showed a slight
increase during this time interval (Table 3).
Few patients had been hospitalized due to pain
or constipation during the 4 weeks immediately
preceding each visit. In total, two patients had
spent 11 days (4 and 7 days, respectively) in
hospital during the 4 weeks immediately
preceding the initiation of oxycodone/naloxone
treatment, and two patients had spent 8 days
(4 days each) in hospital during the 4 weeks
immediately following the initiation of
oxycodone/naloxone.
The mean dose of oxycodone/naloxone was
39.2 mg/day, and the daily doses of oxycodone
varied between 10 and 80 mg. Since some
patients had dose adjustments during the
study period (n = 3), the mean dose was
calculated as a weighted mean based on the
number of days with a specific dose. The dosage
of oxycodone in the participating patients
ranged from low to moderate, corresponding
to approximately 15–120 mg MED (morphine
equivalents per day) [13]. High-dose opioid
therapy has been defined as [200 mg MED
[14], although a recent guideline considers a
MED of[90 mg to be a high dose [2].
After the initiation of oxycodone/naloxone
treatment the patients were asked to score their
global impression of pain relief (global
impression of oxycodone/naloxone), ranging
from 1 (very poor) to 5 (very good). For the
majority of the responding patients the
impression of pain relief was good to very good.
Table 2 Patient characteristics
Variable Patients (n5 37)






Back pain 4 (11%)
Malignancy 12 (32%)
Neuropathic pain 1 (3%)
Otherb 17 (46%)
Values in table are presented as the mean with the
minimum–maximum in parenthesis or as the number of
patients with the percentage in parenthesis, as appropriate
a Primary diagnoses related to pain, several patients had
more than one diagnosis
b For example, other musculoskeletal disorders,
gastrointestinal disorders, and vascular disorders
Table 3 Total number of visits and telephone contacts to different caregivers due to pain and/or constipation in the 4
weeks before and 4 weeks after the initiation of oxycodone/naloxone, respectively
Type of caregiver Visits Calls
Before visit 1a Before visit 2a Before visit 1a Before visit 2a
Specialist physician 10 6 12 0
General practitioner 12 1 6 1
Nurse 3 7 31 10
Other caregiver 1 0 0 0
Total number 26 14 49 11
Total number of patients: 37. Data in table are presented as the number of visits/calls
a The observational study consisted of two visits, i.e., before (visit 1) and after (visit 2) the initiation of oxycodone/naloxone
treatment, covering a total period of 8 weeks (4 weeks before the initiation of treatment and 4 weeks thereafter)
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Purchases of laxatives were higher before the
initiation of oxycodone/naloxone treatment,
with 23 patients reporting that they had
bought laxatives, than after the initiation of
oxycodone/naloxone treatment, with ten
patients reporting such purchases.
No patients in the study had any full-time
employment, and only three patients reported
part-time employment. A majority of the
patients reported that they were retired or
have had an early retirement. Several of the
patients indicated that they were on long-term
sick leave.
Both HRQoL measured with the EQ-5D
instrument and experience of pain intensity
EQ-VAS showed improvements after the
initiation of oxycodone/naloxone, although
the differences were not statistically
significant. The improvements measured by
the disease-specific instruments PAC-QoL,
PAC-SYM, and BFI were all statistically
significant (Table 4).
The direct costs per patient during each of
the 4-week periods preceding visits 1 and 2,
respectively, covering resource utilization
associated with treatment of OIC, with the
exception of costs for analgesics and
prescribed laxatives, are presented in Table 5.
In general, the costs for the 4-week period after
oxycodone/naloxone had been prescribed were
Table 4 Generic and disease-speciﬁc quality-of-life indicators and pain intensity before and after the initiation of
oxycodone/naloxone treatment
Category Visit 1 Visit 2 nh Difference p value
n Mean SD n Mean SD
EQ-5D (0–1)a 37 0.34 0.32 30 0.48 0.32 30 0.10 NS
EQ-5D VAS (0–100)b 35 47.43 18.81 30 55.77 20.82 29 8.55 NS
PAC-QoL (0–96)c
Dissatisfaction index
37 44.19 19.12 31 28.32 20.82 31 -16.94 0.000
PAC-QoL (0–16)d
Satisfaction index
37 4.68 4.08 31 7.23 3.97 31 2.77 0.009
PAC-SYM (0–48)e 37 24.54 8.98 31 17.42 10.33 31 -6.71 0.003
BFI (0–100)f 37 71.86 19.45 30 42.77 28.91 30 -31.60 0.000
Pain intensity (0–10)g 37 4.84 2.25 30 4.07 2.10 30 -0.43 NS
SD standard deviation, NS not signiﬁcant
a EuroQoL ﬁve dimensions (EQ-5D) instrument measures generic quality of life (QoL), with 1 being equal to ‘perfect
health’ and 0 being equal to ‘death’
b EuroQoL visual analog scale (EQ-VAS) instrument, where 100 is equal to the ‘best imaginable health state’ and 0 is equal
to ‘worst imaginable health state’
c Patient Assessment of Constipation-Quality of Life (PAC-QoL) instrument: dissatisfaction index scores range from 0
(‘not at all’ or ‘none of the time’) to 4 (‘extremely’ or ‘all of the time’), with a maximum value of 96
d PAC-QoL instrument: satisfaction index scores range from 0 (‘not at all’ or ‘none of the time’) to 4 (‘extremely’ or ‘all of
the time’), with a maximum value of 16
e Patient Assessment of Constipation Symptoms (PAC-SYM) instrument: scores range from 0 (‘absence of symptoms’) to 4
(‘very severe symptom’), with a maximum value of 48
f Bowel Function Index (BFI) where 0 is equal to ‘no problems’ and 100 is equal to ‘most severe problems’
g Mean pain intensity scores range from 0 (‘no pain’) to 10 (worst pain imaginable’)
h The number of patients that have values both at visit 1 and visit 2
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lower than those for the initial 4-week period
when patients had been treated with
oxycodone and laxatives. The total difference
(EUR100.36, over 28 days) between the two
4-week periods corresponds to an average
cost-saving of EUR3.58/day. In comparison,
the average daily cost of oxycodone/naloxone
was EUR2.32, corresponding to a net
cost-saving of EUR1.26 per day. In addition,
the daily cost of oxycodone and laxatives in the
first 4 weeks of the study period (preceding visit
1) should also be considered in order to estimate
the total cost-savings.
Costs related to adverse events were not
estimated because most adverse events reported
were not related to treatment of pain or OIC.
Indirect costs related to productivity losses
for patients who could not work due to
problems with constipation were not
calculated because no patient indicated that
they had any full-time employment and only
three patients had part-time employment. In
addition, the mean age was high, such that 62%
of the patients were retired. Also, several
patients had malignant diseases, which
probably was the reason for not working.
DISCUSSION
The results of our analysis show that in the 4
weeks immediately after the patients had
started treatment with oxycodone/naloxone,
resource utilization, measured as healthcare
visits, telephone consultations, and purchases
of non-prescribed laxatives, decreased in
comparison to the 4 weeks preceding the
initiation of this treatment regimen when the
patients were treated with oxycodone and
laxatives. The one exception to this decreasing
trend in resource utilization was the slight
increase in number of nurse visits between the
first and second 4-week time interval. A possible
explanation for this trend could be that since
the number of physician visits decreased during
the same period, patients’ problems after
oxycodone/naloxone may have been
considered to be less serious and that a visit to
a nurse was sufficient. The decrease in resource
utilization resulted in decreased costs of
EUR100.36 per patient for the 4-week period,
or EUR3.58/day, compared with the average
daily cost of oxycodone/naloxone of EUR2.32.
At the same time there was a decrease in pain
Table 5 Direct costs per patient during each of the 4-week periods preceding visits 1 and 2, respectively, related to pain and
constipation, excluding costs of oxycodone and prescribed laxatives and costs of oxycodone/naloxone
Direct healthcare costs Direct healthcare costs (EUR, 2015 prices) Difference
(EUR)Before visit 1 (treatment with
oxycodone and laxatives) (n5 37)
Before visit 2 (treatment with
oxycodone/naloxone) (n5 37)
Healthcare visits 109.98 58.25 51.73
Hospitalization 150.17 146.64 3.53




Total 327.17 226.81 100.36
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intensity, although the decrease was not
statistically significant. There were
patient-reported improvements in all QoL
measures following 4 weeks of treatment with
oxycodone/naloxone in comparison to the 4
weeks immediately before initiation of this
treatment, but the differences were only
statistically significant for the two PAC-QoL
measures, PAC-SYM, and for BFI. In addition,
changes in the BFI score of C12 points are likely
to be related to clinically meaningful changes in
the patient’s perception of their bowel habits
[15]. These results are in line with those
reported in other studies which have
demonstrated improved QoL for patients
treated with oxycodone/naloxone [16] and
that oxycodone/naloxone is a cost-effective
option for treating patients with severe pain
and OIC [17, 18].
One limitation of the cost calculation in this
study is that the costs of drugs prescribed during
the 4-week period before the initiation of the
oxycodone/naloxone treatment were not
included. The reason for not including these
data is that a large variety of different types of
drugs and doses were reported for this time
interval. Nevertheless, the cost calculation
shows that treatment with
oxycodone/naloxone in the analyzed patient
population was cost-saving even when only
including costs for hospitalization, healthcare
contacts and over-the-counter purchases of
laxatives. Adding the costs for prescribed drugs
for the period before the initiation of
oxycodone/naloxone treatment would yield an
even larger cost-saving.
In spite of the high occurrence of OIC,
inclusion of patients proved to be very
difficult. One reason for this may be that the
majority of patients referred to the participating
centers had multiple medical and other
problems that either excluded them from the
study or, if the patients were eligible, led them
to decline to participate. The main drawback of
the study is the limited number of patients
available for analysis. It was therefore not
meaningful to perform additional statistical
analyses.
CONCLUSION
The most notable conclusion which can be
drawn from our results is that the
oxycodone/naloxone treatment appeared to
have an overall positive effect on patients. The
effect consisted mainly of lessening the
constipation problems of the patients, which
resulted in increased HRQoL and the
consumption of fewer resources. Statistically
significant changes before and after initiation
of oxycodone/naloxone were found in the
PAC-QoL, PAC-SYM and BFI scores. The results
should be interpreted with caution because of
the small patient sample.
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